ArticlePharmaceutical research2012
Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia.
Article in Pharmaceutical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 80 citations in OpenAlex.
- Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives.Pharmaceutics · 2024Review
- Perspective on the Application of Erythrocyte Liposome-Based Drug Delivery for Infectious Diseases.Membranes · 2022Review
- Different Nanotechnology Approaches for Ciprofloxacin Delivery Against Multidrug-Resistant Microbes.Infection and drug resistance · 2022Review
- Silver Nanoparticles Stabilized by Poly (Vinyl Pyrrolidone) with Potential Anticancer Activity towards Prostate Cancer.Bioinorganic chemistry and applications · 2022Article
- Physicochemical Characteristics and In Vitro Toxicity/Anti-SARS-CoV-2 Activity of Favipiravir Solid Lipid Nanoparticles (SLNs).Pharmaceuticals (Basel, Switzerland) · 2021Article
- Different cellulosic polymers for synthesizing silver nanoparticles with antioxidant and antibacterial activities.Scientific reports · 2021Article
- Aerosolization Performance, Antitussive Effect and Local Toxicity of Naringenin-Hydroxypropyl-β-Cyclodextrin Inhalation Solution for Pulmonary Delivery.AAPS PharmSciTech · 2021Article
- Silver Nanoparticle-Coated Ethyl Cellulose Inhibits Tumor Necrosis Factor-α of Breast Cancer Cells.Drug design, development and therapy · 2021Article
- Novel Therapeutic Strategies Applied toMaterials (Basel, Switzerland) · 2019Review
- Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model.International journal of pharmaceutics · 2019Article
- Temperature-sensitive liposomal ciprofloxacin for the treatment of biofilm on infected metal implants using alternating magnetic fields.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2018Article
- Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection.Pharmaceutical research · 2018Article
- Tuning Ciprofloxacin Release Profiles from Liposomally Encapsulated Nanocrystalline Drug.Pharmaceutical research · 2016Article
- Antibacterial Activity of Ciprofloxacin-Encapsulated Cockle Shells Calcium Carbonate (Aragonite) Nanoparticles and Its Biocompatability in Macrophage J774A.1.International journal of molecular sciences · 2016Article
- Development of Liposomal Ciprofloxacin to Treat Lung Infections.Pharmaceutics · 2016Review
- Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals.Journal of aerosol medicine and pulmonary drug delivery · 2015Article
- Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives.Current pharmaceutical design · 2015Review
- Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties.AAPS PharmSciTech · 2014Article
- New anti-inflammatory targets for chronic obstructive pulmonary disease.Nature reviews. Drug discovery · 2013Review
- Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model.Antimicrobial agents and chemotherapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLiposomal ciprofloxacin nanoparticles were developed to overcome the rapid clearance of antibiotics from the lungs. The formulation was evaluated for its release profile using an air interface Calu-3 cell model and further characterised for aerosol performance and antimicrobial activity.
methodsLiposomal and free ciprofloxacin formulations were nebulised directly onto Calu-3 bronchial epithelial cells placed in an in vitro twin-stage impinger (TSI) to assess the kinetics of release. The aerosol performance of both the liposomal and free ciprofloxacin formulation was characterised using the next generation impactor. Minimum inhibitory and bactericidal concentrations (MICs and MBCs) were determined and compared between formulations to evaluate the antibacterial activity.
resultsThe liposomal formulation successfully controlled the release of ciprofloxacin in the cell model and showed enhanced antibacterial activity against Pseudomonas aeruginosa. In addition, the formulation displayed a respirable aerosol fraction of 70.5 ± 2.03% of the emitted dose.
conclusionResults indicate that the in vitro TSI air interface Calu-3 model is capable of evaluating the fate of nebulised liposomal nanoparticle formulations and support the potential for inhaled liposomal ciprofloxacin to provide a promising treatment for respiratory infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.